These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33705852)

  • 1. Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan.
    Babar ZU; Dodani SK; Nasim A
    Int J Infect Dis; 2021 May; 106():171-175. PubMed ID: 33705852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Microbiological Outcomes in Obese Patients Receiving Colistin for Carbapenem-Resistant Gram-Negative Bloodstream Infection.
    Lam SW; Athans V
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study.
    Ting SW; Lee CH; Liu JW
    J Microbiol Immunol Infect; 2018 Oct; 51(5):621-628. PubMed ID: 28732563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli.
    Gibson GA; Bauer SR; Neuner EA; Bass SN; Lam SW
    Antimicrob Agents Chemother; 2016 Jan; 60(1):431-6. PubMed ID: 26525802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for acute kidney injury in critically ill patients with bacteraemia by carbapenem non-susceptible Gram negative bacteria.
    Papadimitriou-Olivgeris M; Assimakopoulos SF; Kolonitsiou F; Solomou A; Vamvakopoulou S; Spyropoulou A; Karamouzos V; Anastassiou ED; Papachristou E; Spiliopoulou I; Christofidou M; Fligou F; Marangos M
    Infez Med; 2019 Dec; 27(4):380-392. PubMed ID: 31846987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens.
    Yılmaz GR; Baştuğ AT; But A; Yıldız S; Yetkin MA; Kanyılmaz D; Akıncı E; Bodur H
    J Infect Chemother; 2013 Feb; 19(1):57-62. PubMed ID: 22806446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
    Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
    Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
    Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
    BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.
    Kadri SS; Hohmann SF; Orav EJ; Bonne SL; Moffa MA; Timpone JG; Strich JR; Palmore T; Christopher KB; Varughese C; Hooper DC; Danner RL
    Clin Infect Dis; 2015 Jan; 60(1):79-87. PubMed ID: 25246597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
    Nutman A; Lellouche J; Temkin E; Daikos G; Skiada A; Durante-Mangoni E; Dishon-Benattar Y; Bitterman R; Yahav D; Daitch V; Bernardo M; Iossa D; Zusman O; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L; Paul M; Carmeli Y;
    Clin Microbiol Infect; 2020 Sep; 26(9):1185-1191. PubMed ID: 32251844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and safety of colistin usage in pediatric cancer patients with carbapenem-resistant enterobacteriaceae bacteremia at children cancer hospital Egypt.
    Adel N; Khedr R; Elanany M; Zaki HF; Hafez H; El-Abhar H
    Ann Afr Med; 2023; 22(1):82-87. PubMed ID: 36695227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Kasiakou SK; Michalopoulos A; Soteriades ES; Samonis G; Sermaides GJ; Falagas ME
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3136-46. PubMed ID: 16048915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin monotherapy versus colistin-based combination therapy for treatment of bacteremia in burn patients due to carbapenem-resistant gram negative bacteria.
    Park JJ; Seo YB; Lee J; Choi YK; Jeon J
    Burns; 2020 Dec; 46(8):1848-1856. PubMed ID: 32622621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Toxicity of High-Dose Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections: A Comparative Study of a Matched Series.
    Trifi A; Abdellatif S; Daly F; Mahjoub K; Nasri R; Oueslati M; Mannai R; Bouzidi M; Ben Lakhal S
    Chemotherapy; 2016; 61(4):190-6. PubMed ID: 26863534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of broad-spectrum antibiotic exposures and multidrug-resistant gram-negative bacteremia on hematopoietic cell transplantation outcomes.
    Kaundal S; Jandial A; Singh H; Chopra M; Kasudhan KS; Khaire N; Khadwal A; Prakash G; Jain A; Suri V; Patil A; Arora A; Sharma V; Ray P; Malhotra P; Lad DP
    Transpl Infect Dis; 2021 Oct; 23(5):e13717. PubMed ID: 34431187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of clinical characteristics of bacteremia from Elizabethkingia meningoseptica and other carbapenem-resistant, non-fermenting Gram-negative bacilli at a tertiary medical center.
    Huang YC; Wu PF; Lin YT; Wang FD
    J Microbiol Immunol Infect; 2019 Apr; 52(2):304-311. PubMed ID: 30097388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.
    Benattar YD; Omar M; Zusman O; Yahav D; Zak-Doron Y; Altunin S; Elbaz M; Daitch V; Granot M; Leibovici L; Paul M
    Clin Infect Dis; 2016 Dec; 63(12):1605-1612. PubMed ID: 27794023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.
    Vicari G; Bauer SR; Neuner EA; Lam SW
    Clin Infect Dis; 2013 Feb; 56(3):398-404. PubMed ID: 23090926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection.
    Zheng Z; Shao Z; Lu L; Tang S; Shi K; Gong F; Liu J
    BMC Infect Dis; 2023 Oct; 23(1):709. PubMed ID: 37864200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.